EVFMOTCPharmaceutical PreparationsFiscal year ends December 31

Evofem Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$0.01−0.00 (-10.00%)

Close on Oct 19, 2026

Market cap: $865.23K
P/E (TTM): –
Dividend yield: –

Evofem Biosciences, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	20	19	18	17	8.24	0.45	0	–	–	–	–	–	–
Cost of Revenue	4.62	3.83	6.51	4.42	4.06	0.47	0	–	–	–	–	–	–
Gross Profit	16	16	12	12	4.19	-0.02	0	–	–	–	–	–	–
Research & Development	–	1.85	2.94	25	33	17	22	43	24	6.58	34	5.17	11
Selling, General & Admin	17	21	27	72	138	87	31	–	–	–	–	–	–
Selling & Marketing	9.68	9.18	12	44	113	56	10	–	–	–	–	–	–
General & Administrative	7.39	12	15	28	25	30	20	34	12	5.46	7.64	4.42	2.97
Operating Expenses	–	–	–	–	–	104	53	78	36	12	42	9.59	14
Total Costs & Expenses	17	27	36	101	175	104	–	–	–	–	–	–	–
Operating Income	3.37	-7.68	-18	-84	-167	-104	-53	-78	-36	-12	-42	-9.59	-14
Interest Expense	2.37	2.24	2.27	2.18	2.67	2.06	0	–	–	1.04	1.13	0.37	0.06
Interest & Investment Income	0.02	0.02	0.03	0.09	0.02	0.17	0.46	0.13	0.13	0.06	0.03	0.01	0.00
Other Non-Operating Income	-2.98	-1.18	71	7.47	-38	-39	-27	-48	-70	–	–	–	-0.05
Asset Impairment Charges	0.70	0.70	–	0	0	–	–	–	0	0	0	–	–
Gain (Loss) on Sale of Assets	-0.02	-0.73	-2.51	-0.93	0	0	-0.08	0	-0.06	0.00	-0.01	–	-0.05
Pretax Income	0.39	-8.86	53	-77	-205	-142	-80	-126	-105	–	–	–	–
Income Tax Expense	0.00	–	0.02	0.04	0.02	0.00	0.00	0.00	0.00	0	0	0	–
Net Income	0.39	-8.86	53	-77	-205	-142	-80	-126	-105	-13	-43	-11	-15
Preferred Dividends	0.12	0.11	–	0.08	1.05	–	–	–	–	–	–	–	–
Net Income to Common	0.27	-8.97	50	-78	-206	-142	-80	-126	-109	–	–	–	–
EPS (Basic)(per share)	0.00	-0.11	10.36	-167.42	-2,953.75	-3,975.00	-3,731.25	-10,762.50	-104,587.50	-10,612.50	-35,456.25	-60,300.00	-329,962.50
EPS (Diluted)(per share)	0.00	-0.11	0.05	-167.42	-2,953.75	-3,975.00	-3,731.25	-10,762.50	-104,587.50	-10,612.50	-35,456.25	-60,300.00	-329,962.50
Shares Outstanding (Basic, Weighted)(shares)	124	80	4.83	0.47	0.07	0.04	0.02	0.01	0.00	0.00	0.00	0.00	0.00
Shares Outstanding (Diluted, Weighted)(shares)	6,422	80	984	0.47	0.07	0.04	0.02	0.01	0.00	0.00	0.00	0.00	0.00
EBITDA	–	–	-17	-83	-166	-103	-52	-77	-35	-12	-42	-9.57	-14

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 75.5%
Operating margin: -15.3%
Net margin: -84.7%
Return on equity, FY2025: -0.5%

Financial strength

Current ratio: 0.07
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.3%

Valuation

P/E ratio: –
Price to sales: 0.05
Price to book: –
Dividend yield: –